Introduction
EBV is a class I carcinogen according to the World Health Organization and is associated with several B-cell lymphomas including Hodgkin's lymphoma, Burkitt's lymphoma, post-transplantation lymphomas, and certain carcinomas 1 . In lymphomas,
EBV is found associated with almost all cases of post-transplantation lymphomas and endemic Burkitt's lymphoma whereas about 40% and up to 30% of tumor biopsies of Hodgkin's lymphoma and sporadic Burkitt's lymphoma, respectively, are EBV-positive.
EBV is also tightly linked to nasopharyngeal carcinoma in Southeast Asia; in contrast, only about 20% of all cases of gastric adenocarcinomas are EBV-positive 2 . These malignancies appear to be relatively rare because more than 95% of the human population is infected with EBV. In these individuals EBV establishes a benign, latent infection in a small fraction of B cells for a lifetime. In vitro EBV very efficiently infects all only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From human B lymphocytes in a latent mode and growth transforms them into lymphoblastoid cell lines (LCLs). Therefore, transformation of primary B cells by EBV is a hallmark of this virus and constitutes a relevant model system for viral transformation 3 .
In all virus-infected cells EBV adopts a latent state in which viral gene expression is restricted and de novo viral synthesis is abrogated. In LCLs and cases of posttransplantation lymphomas, eleven so-called latent genes are consistently expressed.
These are the EBV nuclear antigens EBNA1, EBNA2, EBNA-LP, EBNA3A, -B, -C, and the latent membrane proteins LMP1, LMP2A, and -B, and two small, non-coding RNAs 3 . Besides these non-coding RNAs, which are expressed in all latently EBV-infected cells, latent viral genes are found in typical combinations in the different EBV-associated tumors. Briefly, in Burkitt's lymphoma almost exclusive and invariant expression of EBNA1 is well documented but LMP2A has also been detetcted in fresh biopsies of this tumor, recently 2, 4 . In nasopharyngeal carcinomas and EBV-positive Hodgkin's lymphomas LMP1 is often expressed in conjunction with EBNA1 and LMP2A and a similar expression profile might also be prevalent in EBV-positive gastric carcinomas 2 .
Although studies clearly show that EBNA1 and LMP1 definitely contribute to cellular transformation 5, 6 , the role of LMP2A remains controversial because it has been reported to be dispensable for B-cell transformation in vitro 7 and references therein but has transforming characteristics in epithelial cells 8 .
LMP2A can constitutively induce several signaling cascades. Its amino-terminal cytoplasmic domain is reminiscent of the signaling domain of the BCR complex because LMP2A as well as the signaling domains of the Igα (CD79A) and Igβ (CD79B) chains of the BCR carry an immunoreceptor tyrosine-based activation motif (ITAM) 9 . Both LMP2A
and BCR signal through Syk, Lyn, Btk, BLNK, AKT, PI3K and other signaling mediators and LMP2A can deliver signals similar to those of an activated BCR 8 ; however, it can also very efficiently block B-cell activation after BCR triggering 9, 10 , preventing the induction of EBV's lytic phase 11 or abrogating B-cell differentiation in vivo 12 . Therefore, it has been proposed that LMP2A might act as a decoy receptor 8, 13 in that it recruits the protein tyrosine kinases Lyn and Syk causing their proteasomal degradation and subsequent inactivation of the BCR signaling complex 8 . Similarly, LMP2A also prevents the BCR from entering lipid rafts after BCR crosslinking blocking both BCR signaling and 
Materials and Methods

Isolation, separation and infection of human primary B cells
Human primary B cells were prepared from adenoids as described previously 19 . BCR Jose, CA). Cell cycle analysis was performed as described previously with the BrdU incorporation kit (BD Biosciences) 19, 21 .
Construction of viral mutants
Two loxP sites were introduced into the genome of 2089 WT EBV in E. coli essentially as described 21 , with the promoter and first exon of LMP2A flanked by two loxP-sites to establish the LMP2A + 2190 EBV genome. The loxP sites were introduced at nucleotide coordinates #166,170 and #166,938 of the prototype EBV genome B95-8 22 . The
LMP2A
-2525 mutant EBV is a derivative of 2190 and was established in E. coli cells harboring p2190 EBV DNA by transient expression of Cre. Virus stocks were prepared from 293HEK producer cell lines as described previously 21 .
Deletion of LMP2A in 2190-infected B cells
Established LCLs were transfected by electroporation using the Amaxa Nucleofector (Amaxa GmbH, Cologne, Germany). Two different expression plasmids were used.
p3233 expresses a bicistronic transcript encoding the truncated version of the NGFreceptor (NGF-R) and the site-specific Cre recombinase (Cre) ( allele; a 418bp PCR product is generated after Cre-mediated deletion of the LMP2A
promoter and the first exon of LMP2A ( Fig. 2A) . Alternatively, the loxP-flanked 
Detection of BZLF1expression levels via RT-PCR
Two and four days after HTNC protein transduction RNA was isolated (Qiagen, Hilden, Germany) and transcribed into cDNA (Invitrogen). Primer oligonucleotides complementary to sequences in the first (P7; 5'-GGAAGCCACCCGATTCTTG) and second (P8; 5'-GAGCCTCTGCCACAAGGC) exon of the BZLF1 gene (Fig. 3C) were used for PCR amplification. The mRNA-specific cDNA of BZLF1 generates a 400bp PCR product whereas the genomic DNA fragment of the corresponding BZLF1 locus is 523bp in length including the first intron in the BZLF1 gene ( Fig. 3B and C) .
Results and Discussion
LMP2A is essential for growth transformation of BCR-negative (BCR -) B cells
To gain insight into the function of LMP2A, we constructed a pair of isogenic viral mutants in E. coli as described previously 24 ; the constructs differed only with respect to the LMP2A gene. Cycling cells could be observed in both BCR +/-and BCR -B-cell populations infected with LMP2A + 2190 EBV as expected four days p.i. (Fig. 1B, C, E For Our results suggest that LMP2A can replace BCR function(s) because BCR -B cells can be rescued and transformed only with an EBV expressing LMP2A, not with an
LMP2A
-mutant (Fig. 1) . Our results also indicate that LMP2A-derived signals dominate or supersede those that originate from basal BCR signaling. Induced loss of LMP2A in BCR + B cells leads to immediate induction of apoptosis (Fig. 2F ). This finding is surprising because several studies have reported that LMP2A is dispensable for growth only.
For Our results suggest that LMP2A is only dispensable for transformation when B cells manage to escape from BCR down-regulation and maintain high levels of BCR expression (Fig. 1D) only.
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